EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

House dust mite SCIT reduces asthma risk and significantly improves long‐term rhinitis and asthma control—A RWE study

Marek Jutel iD, Ludger Klimek iD, Hartmut Richter iD, Bernd Brüggenjürgen iD, Christian Vogelberg iD

Allergy · 2024

DOI: 10.1111/all.16052 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Allergy, 2024. Verfasst von Marek Jutel und 4 weiteren Autor:innen. Beteiligte Einrichtung: ALL-MED Medical Research Institute, Wrocław, Poland. Hauptthemen laut MEDLINE: Asthma, Rhinitis, Allergic. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Allergopharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The German Therapy Allergen Ordinance (TAO) triggered an ongoing upheaval in the market for house dust mite (HDM) allergen immunotherapy (AIT) products. Three HDM subcutaneous AIT (SCIT) products hold approval in Germany and therefore will be available after the scheduled completion of the TAO procedure in 2026. In general, data from clinical trials on the long‐term effectiveness of HDM AIT are rare. We evaluated real‐world data (RWD) in a retrospective, observational cohort study based on a longitudinal claims database including 60% of all German statutory healthcare prescriptions to show the long‐term effectiveness of one of these products in daily life. Aim of this analysis was to provide a per product analysis on effectiveness of mite AIT as it is demanded by international guidelines on AIT.

Methods

Subjects between 5 and 70 years receiving their first (index) prescription of SCIT with a native HDM product (SCIT group) between 2009 and 2013 were included. The exactly 3:1 matched control group received prescriptions for only symptomatic AR medication (non‐AIT group); the evaluation period for up to 6 years of follow‐up ended in February 2017. Study endpoints were the progression of allergic rhinitis (AR) and asthma, asthma occurrence and time to the onset of asthma after at least 2 treatment years.

Results

In total, 892 subjects (608 adults and 284 children/adolescents) were included in the SCIT group and 2676 subjects (1824 adults and 852 children/adolescents) in the non‐AIT group. During the follow‐up period after at least 2 years of SCIT, the number of prescriptions in the SCIT group was reduced by 62.8% ( p < .0001) for AR medication and by 42.4% for asthma medication ( p = .0003). New‐onset asthma risk was significantly reduced in the SCIT vs non‐AIT group by 27.0% ( p = .0212). The asthma‐preventive effect of SCIT occurred 15 months after start of the treatment. In the SCIT group, the time to onset of asthma was prolonged compared to the non‐AIT group ( p = .0010).

Conclusion

In this first product based RWD analysis on SCIT with a native HDM product, patients aged 5 to 70 years benefited from AIT in the long term in terms of reduced progression of AR and asthma after at least 2 years of treatment. The effects seemed to last for up to 6 years after treatment termination. A significantly reduced risk of asthma onset was observed, starting after 15 months of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaRhinitis, AllergicChildAdultAnimalsAdolescentHumansPyroglyphidaeDesensitization, ImmunologicRetrospective StudiesDermatophagoides pteronyssinusAllergensAntigens, Dermatophagoides

Stichwörter der Autor:innen

allergen immunotherapyhouse dust mitelong‐term effectreal‐world evidencesubcutaneous immunotherapy

Substanzen

AllergensAntigens, Dermatophagoides

Autor:innen und Institutionen

  • ALL-MED Medical Research Institute, Wrocław, Poland.
  • Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.
  • Center for Rhinology and Allergology, Wiesbaden, Germany.
  • Epidemiology, IQVIA, Frankfurt am Main, Germany.
  • Institute for Health Services Research and Technical Orthopedics, Orthopedic Clinic of Hannover Medical School, Hannover, Germany.
  • Department of Pneumology and Allergology, Carl Gustav Carus University Clinic, Dresden, Germany.

ORCID-Profile: Marek Jutel, Ludger Klimek, Hartmut Richter, Bernd Brüggenjürgen, Christian Vogelberg

Förderung

  • Allergopharma

Zitieren

APA

Jutel, M., Klimek, L., Richter, H., Brüggenjürgen, B., & Vogelberg, C. (2024). House dust mite SCIT reduces asthma risk and significantly improves long‐term rhinitis and asthma control—A RWE study. Allergy. https://doi.org/10.1111/all.16052

Vancouver

Jutel M, Klimek L, Richter H, Brüggenjürgen B, Vogelberg C. House dust mite SCIT reduces asthma risk and significantly improves long‐term rhinitis and asthma control—A RWE study. Allergy. 2024. doi:10.1111/all.16052

BibTeX
@article{Jutel2024,
  author = {Jutel, Marek and Klimek, Ludger and Richter, Hartmut and Brüggenjürgen, Bernd and Vogelberg, Christian},
  title = {House dust mite SCIT reduces asthma risk and significantly improves long‐term rhinitis and asthma control—A RWE study},
  journal = {Allergy},
  year = {2024},
  doi = {10.1111/all.16052}
}
Kostenlos starten →